Authors' reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
Transl Oncol
.
2022 Nov:25:101528.
doi: 10.1016/j.tranon.2022.101528.
Epub 2022 Sep 7.
Authors
Fredrik H Schjesvold
1
,
Nicolaas A Bakker
2
,
Pieter Sonneveld
3
Affiliations
1
University of Oslo, Oslo University Hospital: Oslo Myeloma Center, Sognsvannsveien 20, Oslo, N-0372, Norway. Electronic address: fredrikschjesvold@gmail.com.
2
Oncopeptides AB, Luntmakargatan 46, SE-111 37, Stockholm, Sweden. Electronic address: Klaas.bakker@oncopeptides.com.
3
Erasmus MC Cancer Institute, Rm Na 2024, PO Box 2040, 3000 CA Rotterdam, the Netherlands. Electronic address: p.sonneveld@erasmusmc.nl.
PMID:
36087383
PMCID:
PMC9468451
DOI:
10.1016/j.tranon.2022.101528
No abstract available
Publication types
Letter